Related Experiment Video
Updated: May 19, 2026
06:18
Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
Published on: March 13, 2018
Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes
David M Bowen1, Jessica A Lewis, Wenzhe Lu
1Computational Biology, Sealy Center for Structural Biology and Molecular Biophysics, Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555-0857, United States.
Vaccine
|August 7, 2012
Summary
Developing a consensus protein antigen for Dengue virus (DENV) is crucial for effective vaccines. This study created a DENV envelope protein domain 3 (EdomIII) consensus sequence that binds antibodies from all four DENV serotypes.
Area of Science:
- Virology
- Immunology
- Protein Engineering
Background:
- Flaviviruses like Dengue virus (DENV) evolve rapidly, necessitating diverse vaccine antigens.
- DENV serotype diversity poses challenges for vaccine development due to potential severe disease upon secondary infection.
Purpose of the Study:
- To design a multivalent antigen representing DENV variability for improved vaccine development.
- To create a consensus protein for Dengue virus envelope protein domain 3 (EdomIII) that elicits broad antibody responses.
Main Methods:
- Derived a physicochemical property (PCP)-consensus sequence from 671 DENV sequences.
- Expressed PCP-consensus EdomIII proteins from synthetic genes in E. coli.
- Tested protein binding to polyclonal antibodies from all four DENV serotypes using ELISA and Western blot.
Main Results:
- An initial consensus protein bound antibodies from DENV-1-3.
- Iterative sequence modification incorporated DENV-4 variability, resulting in a final protein recognized by antibodies against all four serotypes.
- Identified key amino acids within a neutralizing epitope essential for broad antibody binding.
Conclusions:
- The PCP-consensus method efficiently generates multivalent antigens for pathogens like DENV.
- This approach reduces experimental complexity, especially for high-containment pathogens.
- The developed consensus protein shows promise for broad-spectrum DENV vaccine development.
